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1. Introduction  
Non melanoma skin cancers (NMSCs) are the most frequent malignancies in humans (Geller 
& Annas, 2003). It comprises many different types of tumors, such as Squamous Cell 
Carcinoma (SCC) and Basal Cell Carcinoma (BCC), which are the main ones among the 
NMSCs. There are 100.000 new cases of these neoplasms per year in the UK (Aitken et al., 
2007) and about a millon in the US (Kuchide, 2003). NMSC incidence is estimated to increase 
in a 10% by 2060 -taking into account the Copenhagen Amendments scenario for protection 
of ozone layer- (Slaper et al., 1996).  
The development of both SCC and BCC implies a malignant transformation of 
keratinocytes, the most abundant cells in the epidermis. In addition to genetic factors, there 
are a variety of stimulus that can induce this transformation, like viral or bacterial infections 
and chemical agents (such as 7,12-dimethyl benzanthracene -DMBA- or Benzo[a]pyrene-7,8-
diol-9,10-epoxide -B[a]PDE-), (Aubin et al., 2003; Bouwes Bavinck et al., 2001; Madan et al., 
2006). However, the most important carcinogen of the skin is the solar ultraviolet radiation 
(UVr), mainly the UVB component (280-310 nm), which is able to reach the earth surface 
(Armstrong & Kricker, 2001). 
All of those carcinogens promote molecular and cellular changes, modifying different 
functions like cell cycle control or apoptotic cell death. In this way, the affected cells  
lose their capacity to regulate their proliferation properly and have the potential to 
generate an uncontrolled linage of cells, which may ultimately lead to tumor formation 
and growth. 
There are many gene products that have been found to be involved in skin cancer 
development. Some of them are related to cell cycle -like cyclin D1- (Liang et al., 2000), 
apoptosis -like Bax, Bcl-2, and others- or in both processes -like p53 and p21- (Coultas & 
Strasser, 2003; Murphy et al., 2002). Additionally, skin UVB irradiation has been proven to 
induce an increment in the levels of a significant number of immune system mediators, such 
as tumor necrosis factor-ǂ (TNF-ǂ), interleukins 6 (IL-6), 10 (IL-10), 8 (IL-8), 4 (IL-4), 
prostaglandins (PGs), nitric oxide (NO) and vascular endothelial growth factor (VEGF), 
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among others (Paz et al., 2008; Trompezinski et al., 2001). Some of these molecules are known 
to mediate an important outcome of UVB irradiation: immunosuppression. It has been 
vastly proved since Margaret Kripke’s first description (Fisher & Kripke, 1977) that  
UVr-induced DNA damage is not sufficient to lead to skin cancer development; there must 
be a concomitant decrease in normal immunosurvillance (Aubin, 2003; Ullrich & Kripke, 
1984). This immunosuppression is mainly mediated by IL-4, IL-10 and prostaglandin-E2 
(PGE2) (Shreedhar et al., 1998).  
PGs -including PGE2- and thromboxanes (TXs), are subproducts of key enzymes in the 
inflammatory response: cyclooxygenases (COXs). There are two isoforms described for 
COX: COX-1, which is constitutively expressed in many tissues and the inducible isoform 
COX-2, which is up-regulated under physiological and pathophysiological conditions. 
The relationship between COX-2 over-expression and non-melanoma skin cancer 
development and progression has been very well documented and described. Along this 
chapter we will discuss different aspects concerning this relationship, including molecular 
pathways involved in COX-2 expression, cellular effects of COX-2 products and 
experimental treatments for non-melanoma skin cancer, which comprises the modulation of 
the COX-2 pathway. 
2. Molecular pathways involved in COX-2 expression 
COX-2 is a single copy gene, whose location was identified in chromosome 1 by a 
fluorescence in situ hybridization technique (locus 1q25.2-25.3) (Tay et al., 1994). Its gene size 
is about 8 kb and it includes 10 exons with 9 introns, resulting in a primary mRNA of 4.5 kb. 
The expression of this gene, as it was mentioned before, is inducible. There are many factors 
which can contribute to the induction of COX-2 expression, including cytokines, growth 
factors, hormones and bacterial components. 
2.1 COX-2 gene structure 
COX-2 was first described in 1991 by Kujubu et al. (Kujubu et al., 1991) as a primary 
response gene, which encodes an amino acid sequence sharing 61% of identity with the 
COX-1 gene, described in 1988 by Merlie et al. (Merlie et al., 1988). 
 
 
 
Fig. 1. Estructure of COX-2 gene regulatory region.  Transcription regulatory elements  
are shown, their names (above) and upstream position (below with numbers) are 
indicated. 
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In 1995 Inoue et al. analyzed the sequence of the human COX-2 5’-flanking region, 
describing several transcription regulatory elements (Figure 1), which include a TATA box, 
a CRE motif, an E-box, a NF-IL6 motif, three Sp1 sites, two AP-2 sites and two NF-κB sites 
(Inoue et al., 1995). Many animal COX-2 5’-flanking sequences have been characterized, 
exhibiting similar structures in mouse, horse, cow and rat. 
All of these sequence elements have a potential role in the induction of the expression of 
COX-2. Some inducers and the molecular pathways involved in the activation of 
transcription factors, which finally lead to COX-2 expression, are described in the next 
section. 
2.2 Stimulus and mechanisms involved in COX-2 expression 
Prostaglandins and thromboxanes production are intimately related to inflammation, 
besides the fact that they produce a regulation of the overall inflammatory response 
(Ricciotti & FitzGerald, 2011). In this way, it is reasonable that many cytokines and 
molecules involved in the inflammatory process may play some role in the production of 
PGs and TXs. Certainly, TNF-ǂ, IL-1 and Toll-like receptors agonists (like bacterial 
lipopolysaccharide -LPS-) can highly induce the expression of COX-2 gene in many cell 
types. 
Besides the three mentioned molecules, there are other stimuli which are capable of 
inducing COX-2 expression. Other cytokines and different growth factors –like IL-6, EGF, 
FGF and PDGF- may lead to its expression (Tanabe & Tohnai, 2002). Keratinocytes, the most 
abundant cells in the skin, are a cell type that is particularly exposed to natural UVr. This 
stimulus is sufficient to induce the production of many inflammation-related molecules by 
the keratinocytes -such as TNF-ǂ, IL-6 and COX-2 itself- among others (Paz et al., 2008). 
Finally, there are many chemical agents used as tumor promoters (Lim et al., 2011; 
Rundhaug et al., 2007), which are able to induce the expression of COX-2. 
There are two main molecular pathways involved in COX-2 expression (Figures 2 and 3). 
The first one includes the activation of a transcription factor (NF-κB, nuclear factor kappa B) 
and the second one involves the mitogen-activated protein kinases (MAPKs) cascade -with 
three subgroups: p38 MAPK, ERKs and JNK-. 
NF-κB is normally inhibited by IκB binding; this inhibitor can be phosphorylated and 
degraded in the proteasome, releasing the nuclear factor to translocate to the nucleus and to 
start its transcriptional effects. In this pathway the trigger stimuli is related to the interaction 
of membrane receptors with their corresponding agonists, like TNF-ǂ receptor (TNFR), IL-1 
receptor (IL-1R) and Toll-like receptor 4 (TLR-4). As it is shown in Figure 2 there are several 
molecules involved in the pathway, relating the membrane receptors with the 
phosphorylation of IκB. TNFR recruits TRADD (TNFR-associated death domain protein), 
which recruits TRAF-2 (TNFR-associated factor 2), leading to the final common path: 
phosphorylation of NIK (NF-κB-inducing kinase), IKK (IκB kinase complex) and the final 
phosphorylation (and consequent inactivation) of IκB. The other side of this pathway 
comprises IL-1R and TLR-4. Both molecules use MyD88 (Myeloid differentiation factor 88) 
as a linker for the recruitment of IRAK (IL-1R-activated kinase) and the consequent 
phosphorylation of TRAF-6 (TNFR-associated factor 6), which leads to the same final 
common path above mentioned. Once released, NF-κB translocates to the nucleus activating 
the transcription of target genes, like COX-2. 
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Fig. 2. Nuclear factor kappa B -NF-κB- molecular pathway. Membrane receptors with their 
corresponding agonists as trigger stimuli (grey arrows) are shown, also the different 
downstream molecules involved. The common final path, that leads to NF-κB activation and 
subsequent COX-2 expression, can also be seen. P: phosphorylated molecule. 
MAPKs pathway includes a cascade of kinases with specific activity, each of them 
phosphorylates (and activates) the next kinase in the path, ultimately leading to the 
activation of transcription factors which promote the transcription of target genes. This 
pathway is one of the most significant in the activation of COX-2 expression and 
prostaglandins biosynthesis. JNK (c-Jun N-terminal kinase) and p38 MAPK share some of 
the activation stimuli  -like proinflammatory cytokines and bacterial endotoxins- also  
environmental stressors, such as heat shock, oxidative stress and ultraviolet light (highly 
relevant in the development of skin cancer).  On the other hand, ERKs (extracellular-
regulated kinases) are mainly activated by growth factors and oncogenes, like Ras. As it is 
shown in Figure 3, the three MAPKs have individual upstream kinases involved in their 
activation (MAPK kinase). MKK-4/7 activate JNK, while MEK-1/2 activate ERKs and  
MKK-3/6 activate p38. MKKs and MEKs are known as MAPK kinases, and all of them are 
under the control of an upstream kinase (generally named as MAPKK kinase). MAPKK 
kinases are not specific, and in this step the pathways begin to crosslink. We describe only a 
few examples of these MAPKK kinases: the phosphorylation of MKK-4/7 by MEKK 1, 
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MEK-1/2 by Raf-1 (which in turn is activated by Ras oncogene) and MKK-3/6 by RIP. 
Besides these kinases, a family of proteins named SFKs -Src family kinases, including Fyn 
kinase- can directly activate MAPK kinases. Considering the beginning of the pathway, 
MAPKK kinases are activated by STE20 kinases or by GTP-binding proteins (Chang & 
Karin, 2001). Finally, at the end of the pathway MAPK activates transcription factors such as 
AP-1 (homodimers or heterodimers conformed by Jun, Fos, JDP and ATF families) leading 
to an increment in COX-2 expression. Another activated transcription factors can be 
C/EBPs, which play different roles in COX-2 expression, according to the cell type involved 
(Chun & Surh, 2004). 
 
 
Fig. 3. Mitogen-activated protein kinases –MAPKs- molecular pathway. Membrane 
receptors which receive the trigger stimuli are shown, also the different downstream 
molecules involved and their crosslinks. This cascade includes kinases which phosphorylate 
and activate the next kinase. The common final path through the activation of the 
transcription factor AP-1, that finally leads to COX-2 expression, can also be seen. 
In addition to the described mechanisms, there is an intense crosstalk between NF-κB and 
MAPKs pathways (Figure 4). For example, MEKK 1 and RIP are activated by TRAF-2 (Wu & 
Zhou, 2010) and MEKK 1 and JNK can be activated in LPS-treated macrophages through 
and adapter protein, named ECSIT (Kopp et al., 1999). Besides, MEKK 1 is capable of 
phosphorylating IκB, releasing in this way an active NF-κB (Chun & Surh, 2004). 
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Finally, it is worth to notice that there are other pathways involved in the activation of  
NF-κB or MAPKs (Figure 4). For example, Phosphoinositol triphosphate (PIP3, produced by 
active PI3K) activates Akt protein, which is able to phosphorilate IκB, therefore releasing 
active NF-κB (Ouyang et al., 2006).  
 
 
Fig. 4. Crosstalk between MAPKs, PIP3 and NF-κB pathways. Membrane receptors, the 
different downstream molecules involved and their crosslinks are shown. The final path, 
which leads to COX-2 transcription and expression, can also be seen. P: phosphorylated 
molecule. 
3. Molecular and cellular effects of COX-2 products  
COXs -also known as PGH synthases- are the enzymes responsible for the conversion of 
arachidonic acid (AA) into PGH2. AA is released from the cell membrane phospholipids by 
Phospholipase-A2. AA conversion chemical reaction is catalyzed by the two enzymatic 
activities of COXs: cyclooxigenase (or bis-dioxygenase) activity generates a cyclopentane 
hydroperoxy endoperoxide (PGG2) from AA. Peroxidase activity reduces the hydroperoxy 
group yielding the final product PGH2 (Figure 5.a). PGH2 by turns can be transform to 
different products (PGI2 or prostacyclin, PGD2, PGF2a, PGE2 and TXA2) by specific synthases 
(Figure 5.b). 
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All of these AA-derived molecules, which play different roles in many physiological and 
pathophysiological mechanisms, have a short half-life in vivo (from seconds to minutes), 
performing its actions in an autocrine and paracrine fashion, rather than in an endocrine 
way (Ricciotti & FitzGerald, 2011). 
 
 
Fig. 5. Prostaglandins synthesis. a) Conversion of arachidonic acid –AA- into prostaglandin 
H2 -PGH2-, by the two enzymatic activities of COX-2. b) Conversion of PGH2 into different 
final products, by specific synthases. The chemical structures and names of each product are 
shown. 
3.1 Effects of PGE2 on cell cycle and proliferation 
Prostaglandins, particularly PGE2, have been related to cell growth in some cell types. The 
role of PGE2 has been widely described in keratinocytes, as a cell proliferation inducer. 
Indeed, it was described at the end of the 1970 decade, that there was an increase in the 
production of PGE2 in a mouse model of epidermal hyperproliferation -induced by 12-O-
tetradecanoylphorbol-13-acetate (TPA)- (Ashendel & Boutwell, 1979). In this TPA-induced 
proliferation model, keratinocyte growth was effectively blocked using the Non-Steroidal 
Anti-Inflammatory Drug indomethacin and successfully restored with an external 
supplementation of PGE2 (Furstenberger et al., 1979; Furstenberger & Marks, 1978). A few 
years later, Pentland described not only the capacity of keratinocytes to produce their own 
PGs from an external source of AA, but also the autocrine effects of these PGs on the cellular 
growth rate (Pentland & Needleman, 1986). 
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Interestingly, the final effect of PGE2 in a specific cell type depends on the kind of receptor 
expressed in the target cell. There are four types of PGE2 receptors, identified as E 
Prostanoid receptors 1 to 4 (EP1-EP4) (Narumiya et al., 1999; Negishi et al., 1993). These 
receptors are G-protein-coupled receptors which can activate different molecular pathways. 
EP1 acts through the activation of Phospholipase C-ǃ leading to an increase of intracellular 
calcium, while the other three receptors regulate adenylate cyclase activity. Meanwhile EP3 
is able to down-regulate its activity, EP2 and EP4 can up-regulate it (Negishi et al., 1995). 
Other PGs also exert their effects through G-protein-coupled receptor, according to Table 1. 
 
Prostaglandin 
Prostanoid 
Receptor Subtype 
G-protein coupled Molecular Effects 
PGE2 EP1 Gq ↑IP3 
 EP2 Gs ↑ cAMP 
 EP3 Gi, G12, GRho ↓ cAMP, ↑ Ca2+ 
 EP4 Gs ↑ cAMP 
PGD2 DP Gs ↑ cAMP 
 CRTH2 Gi ↓ cAMP, ↑ Ca2+ 
PGF2ǂ FPA, FPB Gq, GRho ↑IP3 
PGI2 IP-IP Gs, Gq, Gi ↑ ↓ cAMP, ↑IP3 
 IP-TPǂ Gs ↑ cAMP 
TxA2 TPǂ, TPǃ 
Gq, Gs, Gi, Gh, 
G12/13 
↑ Ca2+, ↑ ↓ cAMP, 
↑IP3 
Table 1. Molecular effects of prostaglandins –PGs-. The type of PG, subtype of prostanoid 
receptor involved, G-protein-coupled receptor activated and final molecular effect are 
shown. ↑: increase, ↓: decrease, ↑ ↓: both effects are possible. 
Recently, in a study performed using primary mouse keratinocytes, Ansari et al. 
demonstrated that PGE2 is capable of inducing an indirect phosphorilation of epidermal 
growth factor receptor (EGFR), leading to the activation of Ras/MEK/ERK/AP-1 and  
PI3-K/Akt/NF-κB pathways; besides the direct activation of Adenylate cyclase/PKA/CREB 
through EP receptor. Transcription factors CREB, AP-1 and NF-κB lead to its proliferative 
effects through the activation of the expression of cyclin D1 and VEGF (Ansari et al., 2008). 
3.2 Prostaglandins effects on inflammation and immune system 
The involvement of PGs in the inflammatory response has been largely known. The typical 
signs of inflammation -heat, redness, swelling and pain- result from PGs direct effects. 
Indeed, redness and edema are a consequence of an increased vasodilatation and vascular 
endothelium permeability, mediated by the interaction of PGI2 and PGE2 with vascular 
smooth muscle cells, respectively (Funk, 2001; Yamamoto et al., 1999). Besides vascular 
modifications, inflammation-related pain depends on PGE2 stimulation of peripheral 
sensory neurons (Ricciotti & FitzGerald, 2011). Additionally, fever caused in many 
inflammatory processes is also due to the interaction of PGE2 with the nervous system, in 
this case with neurons of the organum vasculosa lamina terminalis at the midline of the 
preoptic area (Funk, 2001). In order to relieve one or all of these effects, inhibitors of PGs 
synthesis have been used as anti-inflammatory drugs for more than a century 
(acetylsalicylic acid was released in 1899 by Bayer), even when their molecular target was 
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unknown. Nowadays, all of the Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) are  
well-known inhibitors of COXs enzymes. There are different groups of NSAIDs each of them 
with diverse mechanisms of action and also selectivity for the two isoforms of the enzyme. 
As it was stated before, PGs and COXs implication in the inflammatory response have been 
described many decades ago. However, the positive feedback loop that involves these 
molecules (Figure 6) should be highlighted, since PGE2 (a sub-product of the enzyme) is able 
to regulate both COX isoforms expression, as it has been proved in keratinocytes. 
Amazingly, not only COX-2 expression was increased but also was COX-1 (Maldve et al., 
2000). The mechanism underlying this feedback involves EP2 receptor and the activation of 
cAMP/CREB pathway (Ansari et al., 2007). 
 
 
Fig. 6. COX-2 expression positive feedback loop. PGE2, through its binding to EP2 receptor, 
activates the cAMP/CREB pathway that finally leads to COX-2 expression, which 
synthesizes more PGE2. 
Besides their direct effects on inflammation, PGs play key roles in the development of the 
immune response, being capable of modifying dendritic cells and T helper (Th) cells 
responses. During the activation of naive Th cells by dendritic cells, or other antigen 
presenting cells, they can differentiate into different phenotypes: Th1 cells (characterized 
by IFN-Ǆ production), Th2 cells (characterized by IL-4 production), Th17 cells 
(characterized by IL-17 production) or Treg cells (characterized by IL-10 production). PGE2 
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plays an important role during this phenotypic differentiation of Th cells. As it has been 
recently reported, PGE2 -through its interaction with both EP2 and EP4- facilitates Th1 cells 
differentiation, by the activation of the PI3K signalling pathway. Moreover, even when it 
was observed that Th17 differentiation was not affected directly by PGE2, an important 
role in IL-23-mediated Th17 cells expansion was proved for PGE2. IL-23 is the cytokine 
involved in the differentiation of naive Th cells into Th17 subset and is produced by 
dendritic cells, which generate endogenous PGE2 that acts in an autocrine way through 
EP4, activating the cAMP-Epac pathway. PGE2 did not substantially affect Th2, while it did 
inhibit Treg differentiation (Yao et al., 2009). Finally, Langerhans cells (the skin-homing 
dendritic cells) require the PGE2-EP4 signalling to mature and migrate from the epidermis 
to the draining lymph nodes, in order to perform an appropriate T cells activation 
(Kabashima et al., 2003). 
4. Skin cancer development and COX-2 over-expression 
Under physiological conditions a balance exists between cell growth and death, resulting 
in a “homeostatic regulation”. In this way, cells are normally under the control of their 
environment. Basically, cancer consists of a group of cells -probably originated from only 
one cell- that presents an “out of control” growth and functional characteristics. Cancer 
cells exhibit six basic acquired capabilities : i) self-sufficiency in growth signals,  
ii) insensitivity to anti-growth signals, iii) evading apoptosis, iv) sustained angiogenesis, 
v) tissue invasion and metastasis and vi) limitless replicative potential (Hanahan & 
Weinberg, 2000). Different signalling pathways can be affected by environmental stimuli, 
affecting normal cell growth. UVB radiation, as it was mentioned before in this chapter, is 
the main environmental carcinogen, affecting in a severe way cell growth control (de 
Gruijl et al., 2001). As it has been vastly proved, specific mutations in the p53 gene and 
over-expression of the p53 protein are present in different types of skin cancer (Bolshakov 
et al., 2003; Brash et al., 1991). However, it is not the only affected gene, as it was 
demonstrated by Kim et al., among others, who evaluated the expression of p53 and  
COX-2 in human skin cancers: SCC, BCC, Bowen’s disease and actinic keratosis. In this 
study it was found that both proteins are over-expressed in skin cancer, but there is not a 
direct correlation between them (Kim et al., 2006). COX-2 over-expression could be a 
consequence of UVB radiation exposure and the subsequent activation of different 
signaling pathways, like the ones which include MAPK, PI3K and NF-κB. 
4.1 Epidemiological data 
It was described that up-regulation of COX-2 expression, which is normally undetected in 
most human tissues, is related to cancer promotion and development. Indeed, COX-2 has 
been evaluated in different human and animal malignancies, and it was stated as a probable 
target for cancer prevention (Hull, 2005; Subbaramaiah & Dannenberg, 2003). 
COX-2 over-expression in different types of non-melanoma skin cancers have been assessed 
by different research groups, mainly by immunohistochemical techniques on human biopsy 
samples. In this way, human samples of SCC, BCC, Bowen’s disease (BD, essentially SCC in 
situ), actinic keratosis (AK, pretumoral lesions that may evolve to SCC) and benign 
papillomas were studied. Sample positive reaction for COX-2 expression (in many cases 
with a highly positive result) ranged between 50 and 91% in SCC, 56 and 80% in BCC, 40 
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and 88% in BD, 50 and 83% in AK and it was of 25% in benign papillomas (An et al., 2002; 
Kagoura et al., 2001; Kim et al., 2006). COX-2 over-expression has also been determined in 
mice models of skin abnormalities, such as hyperplasia of the skin, benign papillomas and 
SCC –resulting from UV chronic irradiation-. In these animal models COX-2 expression was 
also found increased in all cases, in accordance with the results obtained in human biopsy 
samples abovementioned (An et al., 2002; Athar et al., 2001). 
4.2 Relationships between COX-2 expression, UV radiation and skin cancer 
development 
UV radiation, as the main inducer of skin cancer, activates many molecular pathways in skin 
cells. There is a vast bibliography about all of these processes, which we described briefly, 
and it has also been reviewed elsewhere by other authors (Rundhaug & Fischer, 2008). 
COX-2 expression can be induced in humans, proved both in cultured skin cells and in 
whole tissues, after a single or multiple exposures to UVr (Buckman et al., 1998; Tripp et al., 
2003). This molecular response to UVr plays a pivotal role in the development of skin 
malignancies. UVr is able to increase reactive oxygen species (ROS) production, due to an 
excitation of molecules which act as chromophores and that can finally transfer the 
absorbed-energy to molecular oxygen, generating ROS. These molecules produce the 
oxidation of a phosphatase (receptor-type protein tyrosin phosphatase-κ), whose function is 
to keep the epidermal growth factor receptor (EGFR) unphosphorilated and inactive. Once 
the phosphatase is inactivated, EGFR becomes active and can transduce the signal through 
the downstream pathway, which includes Ras/Rac1/p38, leading ultimately to  
COX-2 transcription (Xu et al., 2006a; Xu et al., 2006b). Besides this mechanism, UVr may 
transfer its energy to generate a photoproduct of tryptophan, named 6-formylindolo[2,3-
b]carbazole (FICZ). This molecule is a ligand for arylhydrocarbon receptor (AhR), which 
activates Src kinase and finally leads to the over-expression of COX-2 (Fritsche et al., 2007). 
Another described mechanism underlying UVr-induced COX-2 over-expression is mediated 
by genotoxic damage. UVr directly affects cells by the generation of thymine dimers in the 
DNA; this genotoxic damage activates p53 protein, which arrests cell cycle and regulates the 
activation of apoptotic cell death. p53 also leads to the induction of heparin-binding EGF, 
which activates Ras/Raf/ERK pathway finally mediating the over-expression of COX-2 
(Han et al., 2002). 
COX-2 over-expression leads to the many molecular events described before in this chapter. 
There are some more evidences of the involvement of those molecules and pathways in the 
development of skin cancer. Transgenic mice that express COX-2 constitutively in the  
skin-under the regulation of keratin 5 promoter- were studied in terms of alterations of 
growth or differentiation of the keratinocytes. It was found that constitutive expression of 
COX-2 in keratinocytes generates epidermal hyperplasia, mainly due to a lack of 
differentiation instead of an increased growth rate, and other pathological signs–like 
epidermal invaginations, loss of cell polarity and formation of horn pearls- (Neufang et al., 
2001). Moreover, studies performed in knock-out mice for both COX isoforms demonstrated 
that the absence of any of these enzymes reduces the incidence of skin cancer development, 
in DMBA-TPA model (Tiano et al., 2002a). Finally, the carcinogenic effect of COX-2-derived 
PGE2 is: i) dependent on the expression of EP2, but not of the expression of EP3; since  
knock-out mice lacking these two receptor type respond in different ways to the 
carcinogenic stimuli of DMBA/TPA treatment (Sung et al., 2005) and ii) dependent on EP1; 
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since its specific blockade reduced the number of tumor per mice in a UVB-induced skin 
cancer model (Tober et al., 2006). However, the four prostanoid receptors EP1-EP4 are 
expressed differentially throughout the skin, and developed different staining patterns after 
UVB irradiation, suggesting that each receptor might play dissimilar roles in carcinogenesis 
(Tober et al., 2007). 
5. Chemoprovention and treatment of skin cancer 
Classical treatment for NMSC consists mainly in surgical excision. Particularly, for the case 
of BCC, there is no need to perform a follow-up of the patients, since this type of cancer does 
not have the capacity to metastasize (MacKie, 2006). However, there are enormous efforts 
being made in order to evaluate alternative non-surgical therapies for NMSC. Many of them 
are being studied in animal models, and many others in human patients. We make here a 
brief summary of treatments, highlighting the molecular pathways involved, both for some 
pharmacological and natural compounds. 
5.1 Pharmacological compounds in the skin cancer treatment 
As it was mentioned before, most of the knowledge about the role of COX in the 
development of skin cancer was achieved by studies performed with NSAIDs. In this way, 
the oldest report on the topic was first published, as far as we know, in 1995 (Reeve et al., 
1995). In this study indomethacin (a non-specific NSAID) was administrated in a mouse 
model of UV-induced skin cancer. Many studies were performed since then, facing the issue 
in different ways. Non-specific NSAIDs orally administered have the great disadvantage of 
gastric side-effects, in prolonged treatments. Considering this aspect, the pioneering work of 
Reeve et al. was discussed by Pentland et al., whose work was performed using celecoxib  
–a specific COX-2 inhibitor- in the same model: SKH:1 mice chronically exposed to UV 
radiation (Pentland et al., 1999), results which were further confirmed  (Orengo et al., 2002). 
Pentland demonstrated that, beyond the absence of side-effects, there were much better anti-
tumor results using celecoxib instead of indomethacin. Moreover, these conclusions were 
also achieved by other research group, which directly compared the anti-tumor effects of 
both celecoxib and indomethacin in parallel experiments (Fischer et al., 1999). Oral celecoxib 
treatment was recently evaluated in a randomized, double blind, placebo-controlled trial, 
showing that it would be helpful in the prevention of SCC and BCC in patients who have an 
extensive actinic damage (Elmets et al., 2010).  
In addition to these studies, the idea of skin cancer oral treatments was challenged by 
another way for drugs application: topical treatment. The present book includes a full 
chapter related to the topical administration of drugs and skin cancer, written by Taveira 
& Lopez, which could be of interest. Celecoxib topically applied demonstrated to be 
useful in the suppression of UVB-induced cutaneous inflammation (Wilgus et al., 2000). 
Besides, topically applied naproxen –a non-selective NSAID- was useful in the reduction 
of skin tumors after chronic irradiation of SKH:1 mice, with a marked decrease in the 
levels of PGE2 and a surprising increment in the epidermal production of TNF-ǂ 
(González Maglio et al., 2010). Accordingly, long ago it has been reported that TNF-ǂ 
production increases after the inhibition of COX (Hart et al., 1989). PGE2, as it was stated 
before in this chapter, may act both increasing and decreasing the levels of cAMP  
(a well-known repressor of TNF-ǂ expression). The NSAID-mediated decrease in PGE2 
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production might avoid the inhibition of TNF-ǂ transcription, increasing in this way the 
level of this cytokine in the treated cells (Grandjean-Laquerriere, 2003). Increases in TNF-ǂ 
production may explain, at least in part, another important effect of NSAIDs treatment: 
the induction of apoptosis in the target cells (Fecker et al., 2007). This induction could be 
mediated by TNF-receptor triggered cell death pathway. Moreover, it is worth to notice 
that topical treatment could dramatically reduce the gastric side-effects of non-specific 
NSAIDs prolonged treatment. If this kind of drug application was performed, there 
would be better results in the anti-tumor effects, since both isoforms of COX mediates 
skin cancer development (Tiano et al., 2002b). However, in neither of the commented 
studies the incidence of tumors in treated mice was null, showing that there are cellular 
alterations remaining that cannot be faced with this kind of drugs. 
Aspirin or acetylsalicylic acid –the oldest NSAIDs in use- may capture some special 
attention, since it has been demonstrated that this drug is not only capable of inhibiting 
COX enzymatic activity, but also of inhibiting the activity of IκB kinase-ǃ, inhibiting in this 
way the NF-κB pathway (Yin et al., 1998). 
It is of great interest to analyze another drug, imiquimod, recently approved by the US Food 
and Drug Administration (FDA) to be used topically in the treatment of human SCC and 
BCC (Love et al., 2009). This drug activates directly TLR-7 and TLR-8 and leads to  
the activation of NF-κB and AP-1 nuclear factors, resulting in the expression of  
pro-inflammatory cytokines, and probably –but not proven up to date- COX-2. Another 
mechanism of action includes a decrease in the cellular levels of cAMP which, as it was 
explained before, inhibits the transcription of inflammatory cytokines, like TNF-ǂ. Finally, 
imiquimod can induce directly apoptotic cell death of  tumoral cells through the activation 
of death receptors (Schon & Schon, 2007; Schon et al., 2006). 
Drug treatment of skin cancer might affect the COX-2 pathway, but a reduction in this 
enzyme expression or activity does not necessarily ensure an anti-tumor effect. Besides, by 
only blocking COX activity, the incidence of cancer can be reduced, but not entirely 
abolished. 
5.2 Natural compounds in the skin cancer treatment 
Historically, different human malignancies and pathologies have been treated with 
medicinal plants and different natural extracts. Nowadays, a great number of natural 
compounds with anti-tumor effects have been identified and isolated. Many of them have 
anti-oxidant effects, which are responsible for their protective effects against malignancies. 
A whole chapter of the present book, written by Filip and Clichici, is completely dedicated 
to analyze the use of natural compounds in the treatment of skin cancer. Hereafter, we 
comment the use of some compounds in this field, with some mention to the corresponding 
molecular pathway involved. 
Many natural compounds have the ability of down-regulate in vitro or in vivo the  
UV-induced over-expression of COX-2 or the production of PGE2. Some very well 
documented examples are curcumin (Cho et al., 2005), apigenin (Tong et al., 2007), 
nobiletin (Tanaka et al., 2004), cyanidin (Kim et al., 2010), cyaniding-3-glucoside (Lim et al., 
2011) and ǂ-linoleic acid (Takemura et al., 2002). This capacity of inhibiting COX-2 
expression or function is promising for the use of these compounds in skin cancer 
treatment. However, not all of the above-mentioned compounds have been properly 
assayed in animal tumor models. 
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As an example, cyanidin-3-glucoside (C3G) has been proven to effectively reduce the 
number of papillomas in TPA-treated mice (Ding et al., 2006). C3G was also demonstrated to 
attenuate activation of transcription factors AP-1 and NF-κB, and the kinases MEK, MKK4, 
Akt and MAPKs. However, it does not affect the phosphorylation of the upstream kinase 
Fyn. Molecular docking analysis has demonstrated the capacity of C3G to directly fit in the 
pocket responsible for enzymatic activity of Fyn (Lim et al., 2011). 
Resveratrol was shown to be useful in the treatment of UV-induced skin cancer in mice 
(Aziz et al., 2005). Moreover, it has exhibited an interesting decrease in the activation of  
NF-κB pathway in UVB-exposed cultured keratinocytes (Adhami et al., 2003). 
Pathways which are activated by peroxisome proliferator-activated receptors (PPARs) are 
also of interest. These pathways may be activated by a great number of ligands, including 
pharmacological compounds, fatty acids and fatty acid-derived molecules. PPAR-ǂ can 
modulate the expression of COX-2 and VEGF by antagonizing NF-κB and AP-1, inducing 
the expression of IκB and interfering with the MAPKs pathway (Grau et al., 2008). Indeed, 
PPAR-ǂ expression is down-regulated in human SCC and AK biopsies (Nijsten et al., 2005) 
and its activation has shown a partial inhibition in the development of skin tumors in a mice 
model (Thuillier et al., 2000). Finally, ǂ-linoleic acid (ligand of PPAR-ǂ) can mediate a 
decrease in the UV-induced PGE2 production in SKH:1 mice (Takemura et al., 2002). 
It is worth to notice that all of these compounds, although promising, are not being used in 
humans yet. Many of them remain to be thoroughly tested in animal models, before they 
can be approved for human treatment. Additionally, for natural compounds it is also vacant 
the analysis of the topical administration, since the majority of the studies have been 
performed using the classical oral administration. Topical administration can offer the 
advantages of direct treatment of the lesion and reduction of unwanted side-effects, which 
have not been well-described and reported yet, for the doses of the natural compounds 
needed to exhibit anti-tumor effects.    
6. Conclusion  
COX-2 over-expression is highly related to human NMSC development and progression. 
Many very well known carcinogens can activate different molecular pathways leading to 
COX-2 gene transcription. Over-expression of COX-2 enzyme was determined in human 
NMSC biopsies as well as in animal tissues by different techniques. In vitro studies have 
demonstrated its expression in keratinocytes after carcinogenic stimuli. 
The sub-products of COX-2 enzyme activity, mainly PGE2, lead to many cellular and 
molecular events related with carcinogenesis.  These events include apoptosis resistance, 
growth signalling, angiogenesis and selective immunosuppression. Many of these events are 
regulated by the expression of specific receptors expressed in the target cell. 
A great number of studies have been performed in order to obtain alternative or adjuvant 
treatments for NMSC, different from surgical excision. Treatments which regulate COX-2 
expression pathways or its own enzymatic activity, altered the whole inflammatory 
response, as well as the cellular and molecular events mentioned before. All anti-tumor 
therapies must be analyzed taking into account that malignant-transformed cells can be 
directly eliminated –by avoiding growth stimuli or inducing cytotoxicity- or indirectly –by 
the proper activation of the immune response-. In this way, some of the above-mentioned 
treatments induce preferentially cytotoxic effects, while others increase the immune 
response. For some others, even when the overall anti-tumor effects were effectively proven, 
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the exact mechanism was not. Finally, it is important to highlight that opposite effects on the 
same pathway may result in an equally effective anti-tumor response, i.e. imiquimod 
activates NF-κB pathway while PPAR-ǂ ligands inhibit it, and both are useful treatments for 
NMSC. 
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